Antithrombin references
References
1. Fox KA, Cokkinos DV, Deckers J, Keil U, Maggioni A, Steg G. (2000) The ENACT study: a pan-European survey of acute coronary syndromes. European Network for Acute Coronary Treatment. Eur Heart J 21:1440–1449.
2. Fox KA, Goodman SG, Klein W, Brieger D et al. (2002) Management of acute coronary syndromes. Variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 23:1177–1189.
3. Hasdai D, Behar S, Wallentin L, Danchin N et al. (2002) A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J 23:1190–1201.
4. Hirsch J, Guyatt G, Albers G, Schunemann JH, Munger H et al. Seventh ACCP conference on anti-thrombotic and thromboembolic therapy. Chest 2004;126(suppl 3): S172-696.
5. De Caterina R, Husted S, Wallentin L, Agnelli G, et al.. Anticoagulants in heart disease: current status and perspectives. Eur Heart J 2007 28(7):880-913.
6. Braunwald E, Antman EM, Beasley JW et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2002;40:1366–74.
7. Davie EW, Fujikawa K, Kisiel W. (1991) The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 30:10363–10370.
8. Hoffman M and Monroe DM III. (2001) A cell-based model of hemostasis. Thromb Haemost 85:958–965.
9. Monroe DM, Hoffman M, Roberts HR. (2002) Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 22:1381–1389
10. Belting M, Dorrell MI, Sandgren S et al.. (2004) Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med 10:502–509.
11. Rao LV and Pendurthi UR. (2005) Tissue factor-factor VIIa signaling. Arterioscler Thromb Vasc Biol 25:47–56.
12. Siegbahn A, Johnell M, Sorensen BB et al. (2005) Regulation of chemotaxis by the cytoplasmic domain of tissue factor. Thromb Haemost 93:27–34.
13. Kjalke M, Monroe DM, Hoffman M et al. Active site-inactivated factors VIIa, Xa, and IXa inhibit individual steps in a cell-based model of tissue factor-initiated coagulation. Thromb Haemost. 1998; 80: 578–584.
14. Hoffman M, Monroe DM. A cell based model of hemostasis. Thromb Haemost. 2001; 85: 958–965.
15. Nemerson Y, Repke D. Tissue factor accelerates the activation of coagulation factor VII: the role of a bifunctional coagulation cofactor. Thromb Res. 1985; 40: 351–358.
16. Wildgoose P, Kisiel W. Activation of human factor VII by factors IXa and Xa on human bladder carcinoma cells. Blood. 1989; 73: 1888–1895.
17. Kazama Y, Hamamoto T, Foster DC, Kisiel W. Hepsin, a putative membrane-associated serine protease, activates human factor VII and initiates a pathway of blood coagulation on the cell surface leading to thrombin formation. J Biol Chem. 1995; 270: 66–72.[
18. Warn-Cramer BJ, Maki SL, Zivelin A, Rapaport SI. Partial purification and characterization of extrinsic pathway inhibitor (the factor Xa-dependent plasma inhibitor of factor VIIa/tissue factor). Thromb Res. 1987; 48: 11–22.
19. Broze GJ, Warren LA, Novotny WF et al. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Blood. 1988; 71: 335–343.
20. Monroe DM and Hoffman M. (2005) What does it take to make the perfect clot? Arterioscler Thromb Vasc Biol 26:41–48.
21. Hirsh J and Raschke R. (2004) Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:188S–203S.
22. Raschke RA, Reilly BM, Guidry JR et al. (1993) The weight-based heparin dosing nomogram compared with a ‘standard care’ nomogram. A randomized controlled trial. Ann Intern Med 119:874–881.
23. Bates SM, Weitz JI, Johnston M, Hirsh J, Ginsberg JS. (2001) Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparin. Arch Intern Med 161:385–391.
24. Arepally GM and Ortel TL. (2006) Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med 355:809–817.
25. Collins R, MacMahon S, Flather M et al. (1996) Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. Br Med J 313:652–659.
26. The GUSTO Investigators. (1993) An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329:673–682.
27. Boccara A, Benamer H, Juliard JM et al. (1997) A randomized trial of a fixed high dose vs. a weight-adjusted low dose of intravenous heparin during coronary angioplasty. Eur Heart J 18:631–635.
28. Koch KT, Piek JJ, de Winter RJ et al. (1997) Early ambulation after coronary angioplasty and stenting with six French guiding catheters and low-dose heparin. Am J Cardiol 80:1084–1086.
29. Avendano A and Ferguson JJ. (1994) Comparison of Hemochron and HemoTec activated coagulation time target values during percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 23:907–910.
30. Kereiakes DJ, Lincoff AM, Topol EJ et al. (1998) Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators. Circulation 97:857–864.
31. Kaluski E, Krakover R, Cotter G et al. (2000) Minimal heparinization in coronary angioplasty—how much heparin is really warranted? Am J Cardiol 85:953–956.
32. Silber S, Albertsson P, Aviles FF et al. (2005) Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 26:804–847.
33. Friedman HZ, Cragg DR, Glazier SM et al. (1994) Randomized prospective evaluation of prolonged versus abbreviated intravenous heparin therapy after coronary angioplasty. J Am Coll Cardiol 24:1214–1219.
34. Kakkar VV, Djazaeri B, Fok J, et al. Low-molecular-weight heparin and prevention of postoperative deep vein thrombosis. British medical journal (Clinical research ed. Feb 6 1982;284(6313):375-379.
35. Thomas DP, Merton RE, Lewis WE, et al. Studies in man and experimental animals of a low molecular weight heparin fraction. Thrombosis and haemostasis. Jun 30 1981;45(3):214-218.
36. Weitz JI. Low-molecular-weight heparins. The New England journal of medicine. Sep 4 1997;337(10):688-698.
37. Cella G, Scattolo N, Luzzatto G, et al. Effects of low-molecular-weight heparin on platelets as compared with commercial heparin. Research in experimental medicine. 1984;184(4):227-229.
38. Antman EM, Cohen M, Radley D, et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation. Oct 12 1999;100(15):1602-1608.
39. Bara L, Billaud E, Gramond G, et al. Comparative pharmacokinetics of a low molecular weight heparin (PK 10 169) and unfractionated heparin after intravenous and subcutaneous administration. Thrombosis research. Sep 1 1985;39(5):631-636.
40. Collet JP, Montalescot G, Lison L, et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation. Feb 6 2001;103(5):658-663.
41. Lee S, Gibson CM. Enoxaparin in acute coronary syndromes. Expert review of cardiovascular therapy. May 2007;5(3):387-399.
42. Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Lancet. Mar 2 1996;347(9001):561-568.
43. Gurfinkel EP, Manos EJ, Mejail RI, et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. Journal of the American College of Cardiology. Aug 1995;26(2):313-318.
44. Nurmohamed MT, Rosendaal FR, Buller HR, et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet. Jul 18 1992;340(8812):152-156.
45. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. The New England journal of medicine. Aug 14 1997;337(7):447-452.
46. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation. Oct 12 1999;100(15):1593-1601.
47. Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. Jama. Jul 7 2004;292(1):45-54.
48. Eikelboom JW, Anand SS, Malmberg K, et al. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet. Jun 3 2000;355(9219):1936-1942.
49. Petersen JL, Mahaffey KW, Hasselblad V, et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. Jama. Jul 7 2004;292(1):89-96.
50. Ross AM, Molhoek P, Lundergan C, et al. Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation. Aug 7 2001;104(6):648-652.
51. Van De Werf F, Armstrong P, Granger C et al. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet. Aug 25 2001;358(9282):605-613.
52. Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. The New England journal of medicine. Apr 6 2006;354(14):1477-1488.
53. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation. Aug 31 2004;110(9):e82-292.
54. Boneu, B, Necciari, J, Cariou, R, et al Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/ORG31540) with high affinity to antithrombin III in man. Thromb Haemost 1995;74,1468-1473
55. Tan KT and Lip GY. (2005) Fondaparinux. Curr Pharm Des 11:415–419.
56. Bijsterveld, NR, Moons, AH, Boekholdt, SM, et al Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002;106,2550-2554.
57. Weitz JI, Hirsh J, Samama MM. New anticoagulant drugs: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126: 265S–286S.
58. Linkins LA, Julian JA, Rischke J, et al. (2002) In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation. Thromb Res 107:241–244.
59. Handschin AE, Trentz OA, Hoerstrup SP et al. (2005) Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra) on human osteoblasts in vitro. Br J Surg 92:177–183.
60. Matziolis G, Perka C, Disch A, Zippel H. (2003) Effects of fondaparinux compared with dalteparin, enoxaparin and unfractionated heparin on human osteoblasts. Calcif Tissue Int 73:370–379.
61. Eriksson, BI, Bauer, KA, Lassen, MR, et al Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001;345,1298-1304
62. Lassen, MR, Bauer, KA, Eriksson, BI, et al Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 2002;359,1715-1720
63. Turpie, AG, Bauer, KA, Eriksson, BI, et al Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002;359,1721-1726
64. Bauer, KA, Eriksson, BI, Lassen, MR, et al Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major Simoons ML, Bobbink IW, Boland J, Gardien M, Klootwijk P, Lensing AW, Ruzyllo W, Umans VA, Vahanian A, Van De Werf F, Zeymer U. (2004) A dose-finding study of fondaparinux in patients with non-STsegment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study. J Am Coll Cardiol 43:2183–2190.
65. Buller, HR, Davidson, BL, Decousus, H, et al Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004;140,867-873
66. The MATISSE Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003;349,1695-1702
67. Simoons ML, Bobbink IW, Boland J, Gardien M, Klootwijk P, Lensing AW, Ruzyllo W, Umans VA, Vahanian A, Van De Werf F, Zeymer U. (2004) A dose-finding study of fondaparinux in patients with non-STsegment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study. J Am Coll Cardiol 43:2183–2190.
68. Coussement PK, Bassand JP, Van de Werf F et al. (2001) A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study. Eur Heart J 22:1716–1724.
69. Mehta SR, Steg PG, Yusuf S et al. (2005) Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial. Circulation 111:1390–1397.
70. Vuillemenot A, Schiele F, Meneveau N et al. (1999) Efficacy of a synthetic pentasaccharide, a pure factor Xa inhibitor, as an antithrombotic agent—a pilot study in the setting of coronary angioplasty. Thromb Haemost 81:214–220.
71. Yusuf S, Mehta SR, Chrolavicius S, et al. (2006) Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354:1464–1476.
72. Yusuf S, Mehta SR, Chrolavicius S et al. (2006) Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 295:1519–1530.
73. Nowak G, Schror K. Hirudin - the long and stony way from an anticoagulant peptide in the saliva of medicinal leech to a recombinant drug and beyond. A historical piece. Thrombosis and haemostasis. Jul 2007;98(1):116-119.
74. White CM. Thrombin-directed inhibitors: pharmacology and clinical use. American heart journal. Jan 2005;149(1 Suppl):S54-60.
75. Greinacher A, Eichler P, Albrecht D, et al. Antihirudin antibodies following low-dose subcutaneous treatment with desirudin for thrombosis prophylaxis after hip-replacement surgery: incidence and clinical relevance. Blood. Apr 1 2003;101(7):2617-2619.
76. Serruys PW, Vranckx P, Allikmets K. Clinical development of bivalirudin (Angiox): rationale for thrombin-specific anticoagulation in percutaneous coronary intervention and acute coronary syndromes. International journal of clinical practice. Mar 2006;60(3):344-350.
77. Topol EJ, Bonan R, Jewitt D, et al. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation. May 1993;87(5):1622-1629.
78. de Feyter PJ, van den Brand M, Laarman GJ, et al. Acute coronary artery occlusion during and after percutaneous transluminal coronary angioplasty. Frequency, prediction, clinical course, management, and follow-up. Circulation. Mar 1991;83(3):927-936.
79. Detre KM, Holmes DR, Jr., Holubkov R, et al. Incidence and consequences of periprocedural occlusion. The 1985-1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation. Sep 1990;82(3):739-750.
80. Lincoff AM, Popma JJ, Ellis SG, et al. Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile. Journal of the American College of Cardiology. Apr 1992;19(5):926-935.
81. White H. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet. Dec 1 2001;358(9296):1855-1863.
82. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. Jama. Feb 19 2003;289(7):853-863.
83. Lincoff AM, Kleiman NS, Kereiakes DJ, et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. Jama. Aug 11 2004;292(6):696-703.
84. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. The New England journal of medicine. Nov 23 2006;355(21):2203-2216.
85. Stone GW, White HD, Ohman EM, et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet. Mar 17 2007;369(9565):907-919.
86. Smith SC, Jr., Feldman TE, Hirshfeld JW, Jr., et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation. Feb 21 2006;113(7):e166-286.